2551 - 2560 of 6256 Results
Title
Year
- Discovery, Synthesis, and Preclinical Characterization ofN-(3-Chloro-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-3-amine (VU0418506), a Novel Positive Allosteric Modulator of the Metabotropic Glutamate Receptor 4 (mGlu4)2016OPENTitle: Discovery, Synthesis, and Preclinical Characterization ofN-(3-Chloro-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-3-amine (VU0418506), a Novel Positive Allosteric Modulator of the Metabotropic Glutamate Receptor 4 (mGlu4)Journal Name: ACS Chemical NeurosciencePublisher: American Chemical Society (ACS)Vol: 7Issue #: 9Start Page: 1192End Page: 1200Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1021/acschemneuro.6b00035Best OA location URL: http://doi.org/10.1021/acschemneuro.6b00035Citation Count: 44
- The Parkinson's disease gene product DJ-1 modulates miR-221 to promote neuronal survival against oxidative stress2018OPENTitle: The Parkinson's disease gene product DJ-1 modulates miR-221 to promote neuronal survival against oxidative stressJournal Name: Redox BiologyPublisher: Elsevier BVVol: 19Issue #:Start Page: 62End Page: 73Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.redox.2018.07.021Best OA location URL: https://doi.org/10.1016/j.redox.2018.07.021Citation Count: 81
- Evolving Applications, Technological Challenges and Future Opportunities in Neuromodulation: Proceedings of the Fifth Annual Deep Brain Stimulation Think Tank2018OPENTitle: Evolving Applications, Technological Challenges and Future Opportunities in Neuromodulation: Proceedings of the Fifth Annual Deep Brain Stimulation Think TankJournal Name: Frontiers in NeurosciencePublisher: Frontiers Media SAVol: 11Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3389/fnins.2017.00734Best OA location URL: https://www.frontiersin.org/articles/10.3389/fnins.2017.00734/pdfCitation Count: 70
- Axonal Tract Reconstruction Using a Tissue-Engineered Nigrostriatal Pathway in a Rat Model of Parkinson’s Disease2022OPENTitle: Axonal Tract Reconstruction Using a Tissue-Engineered Nigrostriatal Pathway in a Rat Model of Parkinson’s DiseaseJournal Name: International Journal of Molecular SciencesPublisher: MDPI AGVol: 23Issue #: 22Start Page: 13985End Page: 13985Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3390/ijms232213985Best OA location URL: https://www.mdpi.com/1422-0067/23/22/13985/pdf?version=1668767894Citation Count: 10
- Direct targeting of wild-type glucocerebrosidase by antipsychotic quetiapine improves pathogenic phenotypes in Parkinson’s disease models2021OPENTitle: Direct targeting of wild-type glucocerebrosidase by antipsychotic quetiapine improves pathogenic phenotypes in Parkinson’s disease modelsJournal Name: JCI InsightPublisher: American Society for Clinical InvestigationVol: 6Issue #: 19Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1172/jci.insight.148649Best OA location URL: http://insight.jci.org/articles/view/148649/files/pdfCitation Count: 7
- The protective effect of LRRK2 p.R1398H on risk of Parkinson's disease is independent of MAPT and SNCA variants2013OPENTitle: The protective effect of LRRK2 p.R1398H on risk of Parkinson's disease is independent of MAPT and SNCA variantsJournal Name: Neurobiology of AgingPublisher: Elsevier BVVol: 35Issue #: 1Start Page: 266.e5End Page: 266.e14Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.neurobiolaging.2013.07.013Best OA location URL: https://www.sciencedirect.com/science/article/pii/S0197458013003187Citation Count: 38
- Neuroprotection of low dose carbon monoxide in Parkinson’s disease models commensurate with the reduced risk of Parkinson’s among smokers2024OPENTitle: Neuroprotection of low dose carbon monoxide in Parkinson’s disease models commensurate with the reduced risk of Parkinson’s among smokersJournal Name: npj Parkinson's DiseasePublisher: Springer Science and Business Media LLCVol: 10Issue #: 1Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1038/s41531-024-00763-6Best OA location URL: https://doi.org/10.1038/s41531-024-00763-6Citation Count: 12
- Nigral volumetric and microstructural measures in individuals with scans without evidence of dopaminergic deficit2022OPENTitle: Nigral volumetric and microstructural measures in individuals with scans without evidence of dopaminergic deficitJournal Name: Frontiers in NeurosciencePublisher: Frontiers Media SAVol: 16Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3389/fnins.2022.1048945Best OA location URL: https://www.frontiersin.org/articles/10.3389/fnins.2022.1048945/pdfCitation Count: 4
-
OPENTitle: Decreased Water Mobility Contributes To Increased α‐Synuclein Aggregation**Journal Name: Angewandte Chemie International EditionPublisher: WileyVol: 62Issue #: 7Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-by, cc-byDOI - Digital Object Identifier: 10.1002/anie.202212063Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/anie.202212063Citation Count: 16
- Brain-specific inhibition of mTORC1 eliminates side effects resulting from mTORC1 blockade in the periphery and reduces alcohol intake in mice2021OPENTitle: Brain-specific inhibition of mTORC1 eliminates side effects resulting from mTORC1 blockade in the periphery and reduces alcohol intake in miceJournal Name: Nature CommunicationsPublisher: Springer Science and Business Media LLCVol: 12Issue #: 1Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-by, cc-byDOI - Digital Object Identifier: 10.1038/s41467-021-24567-xBest OA location URL: https://escholarship.org/uc/item/35j6s17tCitation Count: 9